BiotechTube

gemcitabine + mitoxantrone + rituximab

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Conditions

Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Trial Timeline

Dec 1, 2004 → Jan 1, 2008

NCT ID
NCT00656084

About gemcitabine + mitoxantrone + rituximab

gemcitabine + mitoxantrone + rituximab is a phase 2 stage product being developed by Eli Lilly for Relapsed or Refractory Mantle Cell Lymphoma (MCL). The current trial status is completed. This product is registered under clinical trial identifier NCT00656084. Target conditions include Relapsed or Refractory Mantle Cell Lymphoma (MCL).

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00656084Phase 2Completed

Competing Products

20 competing products in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

See all competitors
ProductCompanyStageHype Score
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomideEli LillyPhase 1/2
41
agenT-797MiNK TherapeuticsPhase 1
25
VIP152 + BTKiVincerx PharmaPhase 1
25
eFT508 + AvelumabeFFECTOR TherapeuticsPhase 2
44
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)CelltrionPhase 3
77
AC220Daiichi SankyoPhase 1
33
Valemetostat TosylateDaiichi SankyoPhase 2
52
LinsitinibAstellas PharmaPhase 2
52
AGS67EAstellas PharmaPhase 1
33
Mitoxantrone Hydrochloride Liposome & EnlonstobartSun PharmaceuticalPhase 1/2
41
LenvatinibEisaiPhase 2
52
TazemetostatEisaiPhase 2
52
TazemetostatEisaiPhase 1
33
Eribulin mesylateEisaiPhase 2
52
ME-401Kyowa KirinPhase 1
33
KK2845_1 + KK2845_2 + KK2845_3 + KK2845_4 + KK2845_5 + KK2845_6Kyowa KirinPhase 1
33
MogamulizumabKyowa KirinPhase 2
52
ONO-4685Ono PharmaceuticalPhase 1
33
ONO-4685Ono PharmaceuticalPhase 1
33
Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
77

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85